Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Costa

Showing results (301-310 of 311) with videos related to

Pageof 32
Sort By:
Neurospine|July 4, 2023
Cervical Spondylotic Myelopathy: From the World Federation of Neurosurgical Societies (WFNS) to the Italian Neurosurgical Society (SINch) RecommendationsFrancesco Costa, Carla Daniela Anania, Umberto Agrillo, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 8, 2025
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trialRaffaele Piccolo, Paolo Calabrò, Greta Carrara, et al.
World Neurosurgery: X|February 23, 2023
Relationship between lumbar lordosis, pelvic parameters, PI-LL mismatch and outcome after short fusion surgery for lumbar degenerative disease. Literature review, rational and presentation of public study protocol: RELApSE study (registry for evaluation of lumbar artrodesis sagittal alignEment)Fulvio Tartara, Diego Garbossa, Daniele Armocida, et al.
Expert Opinion on Pharmacotherapy|June 26, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Linda Cingolani, et al.
Intestinal Research|September 29, 2025
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Francesco Costa, et al.
Expert Opinion on Biological Therapy|January 22, 2024
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life studyAntonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.
Advances in Therapy|May 9, 2026
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort StudyAntonio Tursi, Andrea Pasta, Walter Elisei, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Journal of Clinical Medicine|November 13, 2025
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.
Journal of Alzheimer'S Disease : JAD|September 6, 2021
Neuroscience20 (BRAIN20, SPINE20, and MENTAL20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and PoliciesKevin Morris, Mohammad Nami, Joe F Bolanos, et al.
Pageof 32

Showing results (301-310 of 311) with videos related to

Sort By:
Pageof 32
Neurospine|July 4, 2023
Cervical Spondylotic Myelopathy: From the World Federation of Neurosurgical Societies (WFNS) to the Italian Neurosurgical Society (SINch) RecommendationsFrancesco Costa, Carla Daniela Anania, Umberto Agrillo, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 8, 2025
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trialRaffaele Piccolo, Paolo Calabrò, Greta Carrara, et al.
World Neurosurgery: X|February 23, 2023
Relationship between lumbar lordosis, pelvic parameters, PI-LL mismatch and outcome after short fusion surgery for lumbar degenerative disease. Literature review, rational and presentation of public study protocol: RELApSE study (registry for evaluation of lumbar artrodesis sagittal alignEment)Fulvio Tartara, Diego Garbossa, Daniele Armocida, et al.
Expert Opinion on Pharmacotherapy|June 26, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Linda Cingolani, et al.
Intestinal Research|September 29, 2025
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Francesco Costa, et al.
Expert Opinion on Biological Therapy|January 22, 2024
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life studyAntonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.
Advances in Therapy|May 9, 2026
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort StudyAntonio Tursi, Andrea Pasta, Walter Elisei, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Journal of Clinical Medicine|November 13, 2025
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.
Journal of Alzheimer'S Disease : JAD|September 6, 2021
Neuroscience20 (BRAIN20, SPINE20, and MENTAL20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and PoliciesKevin Morris, Mohammad Nami, Joe F Bolanos, et al.
Pageof 32